Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Aug 24;15(8):e44036.
doi: 10.7759/cureus.44036. eCollection 2023 Aug.

Propranolol for the Treatment of Hemangioma in PHACE Syndrome: A Case Report

Tala Beidas  1 , Yara Jazzar  2 , Asem Shadid  3 , Abdulmalik Alhammad  1 , Khaled A Mohajer  1 , Amr M Abduljabbar  1
Affiliations
Case Reports

Propranolol for the Treatment of Hemangioma in PHACE Syndrome: A Case Report

Tala Beidas et al. Cureus. .

Abstract

Oral propranolol is commonly used as a first-line treatment for infantile hemangioma. However, its use in PHACE (posterior fossa anomalies, hemangioma, arterial anomalies, cardiac anomalies, and eye anomalies) syndrome raises concerns that it might exacerbate the patient's risk of stroke. Here, we report the case of a four-month-old premature girl with PHACE syndrome, who presented with a large hemangioma involving the left side of her face, following the V1+V2+V3 distribution, including the upper lip, left ear, and left eye. This condition was successfully treated with propranolol, and no adverse side effects were reported.

Keywords: cleft lip; dandy-walker; hemangioma; phace syndrome; propranolol.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. At four months, before starting treatment, with pus discharge from the lesion.
Figure 2
Figure 2. MRI of the brain showing marked hydrocephalus with a severely dilated fourth ventricle occupying the enlarged posterior fossa.
Figure 3
Figure 3. A few months after starting treatment.
Figure 4
Figure 4. After two years of treatment, IH was cleared
See this image and copyright information in PMC

References

    1. Evaluating the safety of oral propranolol therapy in patients with PHACE syndrome. Olsen GM, Hansen LM, Stefanko NS, et al. https://doi.org/10.1001/jamadermatol.2019.3839. JAMA Dermatol. 2020;156:186–190. - PMC - PubMed
    1. Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants. Metry D, Frieden IJ, Hess C, et al. Pediatr Dermatol. 2013;30:71–89. - PMC - PubMed
    1. PHACE syndrome, a series of six patients: clinical and morphological manifestations, propranolol efficacy, and safety. Bellaud G, Puzenat E, Billon-Grand NC, Humbert P, Aubin F. https://doi.org/10.1111/ijd.12489. Int J Dermatol. 2015;54:102–107. - PubMed
    1. Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome. Gnarra M, Solman L, Harper J, Batul Syed S. https://doi.org/10.1111/bjd.13588. Br J Dermatol. 2015;173:242–246. - PubMed
    1. Siegel DH. UpToDate. Waltham, MA: UpToDate; 2023. PHACE syndrome.

Publication types

LinkOut - more resources